Kirk Taylor - May 1, 2023 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role: Chief Medical Officer
Signature: /s/ Kirk Taylor
Stock symbol: BCLI
Transactions as of: May 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 5/1/2023, 04:24 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCLI	Common Stock	Award	$0	+35K		$0.00	35K	May 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCLI	Stock Option (right to buy)	Award	$0	+80K		$0.00	80K	May 1, 2023	Common Stock	80K	$2.99	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.
F2	The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

Content

Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.

The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.